Exhibit 99.1



MicroVision Announces Fourth Quarter and Full Year 2021 Results

REDMOND, WA / ACCESSWIRE / February 24, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its fourth quarter and full year 2021 results.

“MicroVision made significant progress in 2021, delivering our 1st generation Long Range Lidar sensor early in the year, demonstrating its best-in-class cost advantages and key features, and receiving positive feedback and continued interest from automotive OEMs and Tier 1 suppliers,” said Sumit Sharma, MicroVision’s Chief Executive Officer. “We look forward to track testing our high-speed Highway Pilot system in the U.S. and Germany in Q2 2022.”

“During the past twelve months, we’ve strengthened our balance sheet, increasing our cash position by approximately $100 million and ending the year with $115 million in cash and investments. We are investing in our growth. We grew our employee base from 52 employees last March to 97 employees today and are expanding our R&D labs and testing infrastructure in Redmond. We are pleased with our progress scaling the team and ramping our efforts to be the leading provider of Lidar and ADAS solutions,” continued Sharma.

Key Financial Highlights for Q4 2021



Revenue for the fourth quarter of 2021 was $0.6 million, compared to $0.4 million for the fourth quarter of 2020.



Net loss for the fourth quarter of 2021 was $12.6 million, or $0.08 per share, which includes $2.9 million of non-cash, share-based compensation expense, compared to a net loss of $3.6 million, or $0.02 per share, which includes $0.5 million of non-cash, share-based compensation expense, for the fourth quarter of 2020.



Adjusted EBITDA for the fourth quarter of 2021 was negative $9.3 million, compared to negative $2.9 million in the fourth quarter of 2020.



Cash used in operations in 2021 was $29.4 million, compared to cash used in operations in 2020 of $16.1 million.



The Company ended the fourth quarter of 2021 with $115.4 million in cash and cash equivalents including investment securities, compared to $16.9 million at the end of the fourth quarter of 2020.

Conference Call and Webcast: Q4 and Full Year 2021 Results

MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Thursday, February 24, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on February 24, 2022.

The live webcast and slide presentation can be accessed on the Company’s Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.

About MicroVision

MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company’s integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.

For more information, visit the Company’s website at www.microvision.com, on Facebook at www.facebook.com/microvisioninc or follow MicroVision on Twitter at @MicroVision. MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Non-GAAP information

To supplement MicroVision’s condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure “adjusted EBITDA.” Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.

MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision’s past financial reports, and facilitates comparisons with other companies in the Company’s industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company’s operating results and facilitates comparisons of the Company’s core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision’s operating performance and the valuation of the Company.

Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision’s business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.

MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.

Forward-Looking Statements

Certain statements contained in this release, including the Company’s plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.

Balance Sheet

(In thousands)



     December 31,     December 31,  
     2021     2020  



Current Assets


Cash and cash equivalents

   $ 82,647     $ 16,862  

Investment securities, available-for-sale

     32,720       —    


     1,780       —    

Other current assets

     2,283       698  







Total current assets

     119,430       17,560  

Property and equipment, net

     3,026       1,883  

Operating lease right-of-use asset

     5,577       946  

Restricted cash

     1,092       435  

Intangible assets, net

     115       164  

Other assets

     985       18  







Total assets

   $ 130,225     $ 21,006  







Liabilities and Shareholders’ Equity


Current Liabilities


Accounts payable

   $ 3,584     $ 630  

Accrued liabilities

     1,170       495  

Contract liabilities

     5,265       7,765  

Other current liabilities

     1,181       —    

Current portion of long-term debt

     392       431  

Current portion of operating lease liability

     849       676  

Current portion of finance lease obligations

     21       31  







Total current liabilities

     12,462       10,028  

Long term debt, net of current portion

     —         1,151  

Operating lease liability, net of current portion

     4,983       774  

Finance lease obligations, net of current portion

     26       44  







Total liabilities

     17,471       11,997  







Commitments and contingencies


Shareholders’ Equity


Common stock at par value

     164       153  

Additional paid-in capital

     742,042       601,224  

Subscriptions receivable

     —         (6,135

Accumulated other comprehensive loss

     (19     —    

Accumulated deficit

     (629,433     (586,233







Total shareholders’ equity

     112,754       9,009  







Total liabilities and shareholders’ equity

   $ 130,225     $ 21,006  







MicroVision, Inc.

Statement of Operations

(In thousands, except earnings per share data)



     Three months ended
December 31,
    Twelve months ended
December 31,
     2021     2020     2021     2020  

Product revenue

   $ —       $ —       $ —       $ 1,347  

License and royalty revenue

     557       395       2,500       1,718  

Contract revenue

     —         —         —         25  













Total revenue

     557       395       2,500       3,090  













Cost of product revenue

     48       —         2       1,394  

Cost of contract revenue

     —         —         —         4  













Total cost of revenue

     48       —         2       1,398  













Gross margin

     509       395       2,498       1,692  













Research and development expense

     6,482       2,578       24,111       9,840  

Sales, marketing, general and administrative expense

     6,648       1,381       22,256       5,917  

Gain on disposal of fixed assets

     —         —         —         (450













Total operating expenses

     13,130       3,959       46,367       15,307  













Loss from operations

     (12,621     (3,564     (43,869     (13,615

Gain on debt extinguishment

     —         —         692       —    

Other expense, net

     (4     (6     (23     (19













Net loss

   $ (12,625   $ (3,570   $ (43,200   $ (13,634













Net loss per share - basic and diluted

   $ (0.08   $ (0.02   $ (0.27   $ (0.10













Weighted-average shares outstanding - basic and diluted

     164,220       148,176       160,662       139,829  













MicroVision, Inc.

Reconciliation of GAAP Net Loss to Non-GAAP Measure

(In thousands, except earnings per share data)



     Three months ended
December 31,
    Twelve months ended
December 31,
     2021     2020     2021     2020  

GAAP net loss

   $ (12,625   $ (3,570   $ (43,200   $ (13,634

Add Interest (net)

     (2     5       7       14  

Add Income taxes

     —         —         —         —    

Add Depreciation & amorization

     424       237       1,464       963  

Add Share-based compensation expense

     2,937       458       15,282       1,297  













Adjusted EBITDA

   $ (9,266   $ (2,870   $ (26,447   $ (11,360













Investor Relations Contact

Jeff Christensen and Matt Kreps

Darrow Associates Investor Relations


SOURCE: MicroVision, Inc.